Ascophyllum nodosum, fucus vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients

Research output: Contribution to journalArticle

Abstract

Aim: To evaluate the actions of a combination of polifenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus, InSea2®) and chromium picolinate compared to placebo in addition to previously taken anti-diabetic therapy in patients with type 2 diabetes. Methods: 175 Caucasian patients with type 2 diabetes were randomized to take nutraceutical combination or placebo for 6 months. One hundred and sixty-four cases completed the study. At baseline and after 6 months, glyco-metabolic control and lipid profile were evaluated. Results: Glycated hemoglobin was significantly reduced by the nutraceutical combination, but not by placebo, both compared to baseline (p<0.05), and compared to placebo (p<0.05). A similar trend was recorded for fasting plasma glucose (FPG) [−23.5% (p<0.01) vs baseline, and −18.0% (p<0.01) vs placebo] and post-prandial glucose (PPG) [−17.1% (p<0.01) vs baseline, and −11.1% (p<0.05) vs placebo]. No variations of lipid profile were recorded compared to baseline, even if it seems to observe a reduction trend of triglycerides level in the nutraceutical group. Conclusion: In conclusion, a nutraceutical combination of polifenolic composition and chromium picolinate in addition to previously taken anti-diabetic therapy can be helpful in reducing glycated hemoglobin in patients with type 2 diabetes mellitus.

Original languageEnglish
Pages (from-to)1861-1865
Number of pages5
JournalDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Volume12
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Ascophyllum
Fucus
Dietary Supplements
Placebos
Type 2 Diabetes Mellitus
Glycosylated Hemoglobin A
Lipids
Glucose
Meals
picolinic acid
Fasting
Triglycerides
Therapeutics

Keywords

  • Ascophyllum Nodosum
  • Chromium
  • Fucus Vesiculosus
  • Glycemic control

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology

Cite this

@article{244c938aa1194476a963e0049bb3addc,
title = "Ascophyllum nodosum, fucus vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients",
abstract = "Aim: To evaluate the actions of a combination of polifenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus, InSea2{\circledR}) and chromium picolinate compared to placebo in addition to previously taken anti-diabetic therapy in patients with type 2 diabetes. Methods: 175 Caucasian patients with type 2 diabetes were randomized to take nutraceutical combination or placebo for 6 months. One hundred and sixty-four cases completed the study. At baseline and after 6 months, glyco-metabolic control and lipid profile were evaluated. Results: Glycated hemoglobin was significantly reduced by the nutraceutical combination, but not by placebo, both compared to baseline (p<0.05), and compared to placebo (p<0.05). A similar trend was recorded for fasting plasma glucose (FPG) [−23.5{\%} (p<0.01) vs baseline, and −18.0{\%} (p<0.01) vs placebo] and post-prandial glucose (PPG) [−17.1{\%} (p<0.01) vs baseline, and −11.1{\%} (p<0.05) vs placebo]. No variations of lipid profile were recorded compared to baseline, even if it seems to observe a reduction trend of triglycerides level in the nutraceutical group. Conclusion: In conclusion, a nutraceutical combination of polifenolic composition and chromium picolinate in addition to previously taken anti-diabetic therapy can be helpful in reducing glycated hemoglobin in patients with type 2 diabetes mellitus.",
keywords = "Ascophyllum Nodosum, Chromium, Fucus Vesiculosus, Glycemic control",
author = "Giuseppe Derosa and Pascuzzo, {Maria Divina} and Angela D'angelo and Pamela Maffioli",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/DMSO.S212429",
language = "English",
volume = "12",
pages = "1861--1865",
journal = "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy",
issn = "1178-7007",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Ascophyllum nodosum, fucus vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients

AU - Derosa, Giuseppe

AU - Pascuzzo, Maria Divina

AU - D'angelo, Angela

AU - Maffioli, Pamela

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: To evaluate the actions of a combination of polifenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus, InSea2®) and chromium picolinate compared to placebo in addition to previously taken anti-diabetic therapy in patients with type 2 diabetes. Methods: 175 Caucasian patients with type 2 diabetes were randomized to take nutraceutical combination or placebo for 6 months. One hundred and sixty-four cases completed the study. At baseline and after 6 months, glyco-metabolic control and lipid profile were evaluated. Results: Glycated hemoglobin was significantly reduced by the nutraceutical combination, but not by placebo, both compared to baseline (p<0.05), and compared to placebo (p<0.05). A similar trend was recorded for fasting plasma glucose (FPG) [−23.5% (p<0.01) vs baseline, and −18.0% (p<0.01) vs placebo] and post-prandial glucose (PPG) [−17.1% (p<0.01) vs baseline, and −11.1% (p<0.05) vs placebo]. No variations of lipid profile were recorded compared to baseline, even if it seems to observe a reduction trend of triglycerides level in the nutraceutical group. Conclusion: In conclusion, a nutraceutical combination of polifenolic composition and chromium picolinate in addition to previously taken anti-diabetic therapy can be helpful in reducing glycated hemoglobin in patients with type 2 diabetes mellitus.

AB - Aim: To evaluate the actions of a combination of polifenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus, InSea2®) and chromium picolinate compared to placebo in addition to previously taken anti-diabetic therapy in patients with type 2 diabetes. Methods: 175 Caucasian patients with type 2 diabetes were randomized to take nutraceutical combination or placebo for 6 months. One hundred and sixty-four cases completed the study. At baseline and after 6 months, glyco-metabolic control and lipid profile were evaluated. Results: Glycated hemoglobin was significantly reduced by the nutraceutical combination, but not by placebo, both compared to baseline (p<0.05), and compared to placebo (p<0.05). A similar trend was recorded for fasting plasma glucose (FPG) [−23.5% (p<0.01) vs baseline, and −18.0% (p<0.01) vs placebo] and post-prandial glucose (PPG) [−17.1% (p<0.01) vs baseline, and −11.1% (p<0.05) vs placebo]. No variations of lipid profile were recorded compared to baseline, even if it seems to observe a reduction trend of triglycerides level in the nutraceutical group. Conclusion: In conclusion, a nutraceutical combination of polifenolic composition and chromium picolinate in addition to previously taken anti-diabetic therapy can be helpful in reducing glycated hemoglobin in patients with type 2 diabetes mellitus.

KW - Ascophyllum Nodosum

KW - Chromium

KW - Fucus Vesiculosus

KW - Glycemic control

UR - http://www.scopus.com/inward/record.url?scp=85073426468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073426468&partnerID=8YFLogxK

U2 - 10.2147/DMSO.S212429

DO - 10.2147/DMSO.S212429

M3 - Article

AN - SCOPUS:85073426468

VL - 12

SP - 1861

EP - 1865

JO - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

JF - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

SN - 1178-7007

ER -